SMR3B

Across TCGA pan-cancer cohorts, SMR3B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMR3B data layer compared with 9 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SMR3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMR3B expression acts as an unfavorable survival marker.

GBM, SARC, and ESCA are the cancer types where SMR3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.055	0.416	<.001	15	view →
SARC	DFS	Median	All	0.108	0.613	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.343	0.691	.013	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SMR3B–GBM (OS)

Open the GBM breakdown →